Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4024956 | 0.91 | AR (0.77) | ARHDAC1 | |
| SCHEMBL13647000 | 0.90 | AR (0.74) | ARHDAC1 | |
| SCHEMBL23260981 | 0.90 | AR (0.72) | ARHDAC1 | |
| SCHEMBL13647001 | 0.90 | AR (0.72) | ARHDAC1 | |
| SCHEMBL8704637 | 0.89 | AR (0.77) | ARHDAC1 | |
| SCHEMBL4027208 | 0.89 | AR (0.74) | AR | |
| SCHEMBL7779111 | 0.89 | AR (0.78) | ARHDAC1 | |
| SCHEMBL8516863 | 0.88 | AR (0.79) | ARHDAC1 | |
| SCHEMBL8516366 | 0.88 | AR (0.70) | ARHDAC1 | |
| SCHEMBL4020463 | 0.88 | AR (0.77) | ARHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024073626-A2 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2016118666-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR | Arvinas, Inc. (US) | 2016-07-28 | — | — | WO | disclosed |
| US-7601748-B2 | Anti-androgenic N-[ omega -[3-[4-cyano-3-(trifluoromethyl)-phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]alkyl]-substituted pyrrolidines; treatment of prostate cancer, benign prostate hyperplasia, androgenetic alopecia, hirsutism or acne | BAYER SCHERING PHARMA AG (DE) | 2009-10-13 | — | — | US | disclosed |
| WO-2009097996-A1 | USE OF SUBSTITUTED PHENYLIMIDAZOLIDINES FOR PRODUCING MEDICAMENTS FOR TREATING METABOLIC SYNDROME | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| US-20070021481-A1 | Anti-androgenic pyrrolidines with tumor-inhibiting action | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-25 | — | — | US | disclosed |
| EP-0671156-B1 | Process to prepare cosmetic or pharmaceutical compositions containing liposomes | AVENTIS PHARMA SA (FR) | 2001-10-24 | — | — | EP | disclosed |
| US-6162444-A | Cosmetic or pharmaceutical compositions | HOECHST MARION ROUSSEL (FR) | 2000-12-19 | — | — | US | disclosed |
| US-RE35956-E | Phenylimidazolidines having antiandrogenic activity | ROUSSEL UCLAF (FR) | 1998-11-10 | — | — | US | disclosed |
| US-5627201-A | Phenylimidazolidines having antiandrogenic activity | ROUSSEL UCLAF (FR) | 1997-05-06 | — | — | US | disclosed |
| EP-0494819-B1 | Phenylimidazolidines, their process for fabrication, their application as medicaments and the pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1996-07-10 | — | — | EP | disclosed |
| EP-0671156-A1 | Cosmetic or pharmaceutical compositions containing liposomes | ROUSSEL UCLAF (FR) | 1995-09-13 | — | — | EP | disclosed |
| US-5411981-A | Phenylimidazolidines having antiandrogenic activity | ROUSSEL UCLAF (FR) | 1995-05-02 | — | — | US | disclosed |
| EP-0494819-A1 | Phenylimidazolidines, their process for fabrication, their application as medicaments and the pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1992-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021481-A1 | Anti-androgenic pyrrolidines with tumor-inhibiting action | NR5A1, AR, CYP17A1 | AR 2/4885HDAC1 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.